Model-based assessment of public health impact and cost-effectiveness of dengue vaccination following screening for prior exposure

The tetravalent dengue vaccine CYD-TDV (Dengvaxia) is the first licensed vaccine against dengue, but recent findings indicate an elevated risk of severe disease among vaccinees without prior dengue virus (DENV) exposure. The World Health Organization currently recommends CYD-TDV only for individuals...

Descripción completa

Detalles Bibliográficos
Autores principales: España, Guido, Yao, Yutong, Anderson, Kathryn B., Fitzpatrick, Meagan C., Smith, David L., Morrison, Amy C., Wilder-Smith, Annelies, Scott, Thomas W., Perkins, T. Alex
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6625736/
https://www.ncbi.nlm.nih.gov/pubmed/31260441
http://dx.doi.org/10.1371/journal.pntd.0007482

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6625736/
https://www.ncbi.nlm.nih.gov/pubmed/31260441
http://dx.doi.org/10.1371/journal.pntd.0007482

Ejemplares similares